|
Since I registered I am having problems in posting. I cant paste and have lost posts midstream. Until I sort it out I'm afraid I cant post the links.
I have done a quick search on omega three and the chemo agent cited paclitaxel and doxorubicin.
Both trials suggested the omega three derivates tested had synergystic effects on the chemo agent.
At a simple level this suggests the mechaninsms of omega three derivatives are different from that of Decadron.
This raises interesting issues. Would the inhibition of fas also inhibit elongation of omega three fats (assuming it is available in diet). What would be the impact of inhibiting synthesis of omega threes.
Might decadron inhibit inflamatory omega sixes and therby restrict cancerous growth but also have negative impact in terms of restricting omega threes elonated products DHA EPA and at what cost to other organ performance, if fas blocking is not restricted to breast.
RB
|